Opendata, web and dolomites

IRIS Phase-1 SIGNED

A revolutionary blood test to easily diagnose and prevent deadly complications of organs and tissue transplants.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IRIS Phase-1 project word cloud

Explore the words cloud of the IRIS Phase-1 project. It provides you a very rough idea of what is the project "IRIS Phase-1" about.

enzyme    serious    host    diagnose    biopsies    3beta    unfortunately    scanner    time    tens    detect    progression    chip    published    marrow    adoption    lasts    poses    invasive    patients    property    suspected    when    disposable    donour    bone    cells    limiting    treatments    option    critical    sound    wasted    graft    risk    saving    transplantations    portfolio    disease    people    stage    months    antibodies    gsk    swift    receiving    hospitalization    blood    fluorescence    mortality    representing    complications    onset    market    laboratory    proliferation    enclosed    diagnosis    drug    strategy    appear    solution    treatment    attack    certain    life    diagnostic    versus    period    validate    link    monitor    trials    starting    plan    threat    intellectual    clinical    weeks    donor    standard    aggressive    protein    cancers    scientific    knowhow    patent    instead    first    linked    world    symptoms    biopsy    95    transplants    severe    stronger    marxbio    protected    kit    company    80    occurs   

Project "IRIS Phase-1" data sheet

The following table provides information about the project.

Coordinator
MARX BIOTECHNOLOGY LTD 

Organization address
address: MA'AVAR HAMITLA 3
city: Jerusalem
postcode: 9776106
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MARX BIOTECHNOLOGY LTD IL (Jerusalem) coordinator 50˙000.00

Map

 Project objective

Transplantations are life-saving treatments, often representing the only option for people with severe disease such as blood cancers. Unfortunately, complications linked to transplants are so high that they are current limiting the increase of adoption of transplantations. Specifically, Graft versus Host Disease occurs in up to 80% cases after receiving bone marrow from a donour and poses a serious threat to the life of patients already in critical condition. Graft versus Host Disease, today, can only be suspected when it is already at an advanced state, i.e. when clinical symptoms appear. However, symptoms are not unique, thus invasive biopsies are needed for a certain diagnosis. At this stage, even more time has been wasted before starting an effective drug treatment: the mortality risk can reach 95%, the hospitalization period lasts months instead than weeks and so drug treatments, that have to be stronger and more aggressive. MarxBio for the first time in the world was able to link a particular enzyme called GSK-3beta to the onset of Graft versus Host Disease and, specifically, to the proliferation of donor’s T-cells that attack the host. The Company has the unique knowhow to monitor the complex pathways of GSK-3beta to diagnose and monitor the progression of the disease, through the use of tens of different, specific antibodies. All of this know-how has been enclosed in a disposable protein chip, so a simple blood test, instead of a biopsy, is required to detect the disease: results can be obtained in every laboratory, with the use of a standard fluorescence scanner. Scientific results have been published and intellectual property has been protected with a patent portfolio. During Phase 1 project the Company will assess the scale-up plan and the clinical trials to be conducted to validate the diagnostic kit, and will establish a sound go-to-market strategy to ensure a swift market uptake of the proposed solution.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IRIS PHASE-1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IRIS PHASE-1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More